Free Access
Med Sci (Paris)
Volume 27, Number 6-7, Juin–Juillet 2011
Page(s) 633 - 638
Section M/S Revues
Published online 01 July 2011
  1. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003 ; 3 : 243-252. [CrossRef] [PubMed] [Google Scholar]
  2. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008 ; 5 : 588-599. [CrossRef] [PubMed] [Google Scholar]
  3. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. Febs J 2009 ; 276 : 6880-6904. [CrossRef] [PubMed] [Google Scholar]
  4. Soussi T. p53 Antibodies in the sera of patients with various types of cancer : a review. Cancer Res 2000 ; 60 : 1777-1788. [PubMed] [Google Scholar]
  5. Schubert U, Antón LC, Gibbs J, et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000 ; 404 : 770-774. [CrossRef] [PubMed] [Google Scholar]
  6. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997 ; 94 : 1914-1918. [CrossRef] [Google Scholar]
  7. Ulanet DB, Torbenson M, Dang CV, et al. Unique conformation of cancer autoantigen B23 in hepatoma : a mechanism for specificity in the autoimmune response. Proc Natl Acad Sci U S A 2003 ; 100 : 12361-12366. [CrossRef] [PubMed] [Google Scholar]
  8. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000 ; 86 : 702-712. [CrossRef] [PubMed] [Google Scholar]
  9. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010 ; 70 : 1306-1313. [CrossRef] [PubMed] [Google Scholar]
  10. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001 ; 98 : 12659-12664. [CrossRef] [Google Scholar]
  11. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003 ; 21 : 37-38. [CrossRef] [PubMed] [Google Scholar]
  12. Anderson KS, LaBaer J. The sentinel within : exploiting the immune system for cancer biomarkers. J Proteome Res 2005 ; 4 : 1123-1133. [CrossRef] [PubMed] [Google Scholar]
  13. Li Y, Karjalainen A, Koskinen H, et al. p53 autoantibodies predict subsequent development of cancer. Int J Cancer 2005 ; 114 : 157-160. [CrossRef] [PubMed] [Google Scholar]
  14. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006 ; 355 : 1763-1771. [CrossRef] [PubMed] [Google Scholar]
  15. Madoz-Gúrpide J, Kuick R, Wang H, Misek DE, Hanash SM. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 2008 ; 7 : 268-281. [PubMed] [Google Scholar]
  16. Chen G, Wang X, Yu J, Varambally S, et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007 ; 67 : 3461-3467. [CrossRef] [PubMed] [Google Scholar]
  17. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer : possibilities for early detection and subsequent cure. Thorax 2008 ; 63 : 228-233. [CrossRef] [PubMed] [Google Scholar]
  18. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011 ; 22 : 383-389. [CrossRef] [PubMed] [Google Scholar]
  19. Leidinger P, Keller A, Ludwig N, et al. Toward an early diagnosis of lung cancer : an autoantibody signature for squamous cell lung carcinoma. Int J Cancer 2008 ; 123 : 1631-1636. [CrossRef] [PubMed] [Google Scholar]
  20. Leidinger P, Keller A, Heisel S, et al. Identification of lung cancer with high sensitivity, specificity by blood testing. Respir Res 2010 ; 11 : 18. [CrossRef] [PubMed] [Google Scholar]
  21. Launoy G. Epidemiology of cancers in France. Rev Prat 2010 ; 60 : 178-182. [PubMed] [Google Scholar]
  22. Desmetz C, Bascoul-Mollevi C, Rochaix P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009 ; 15 : 4733-4741. [CrossRef] [PubMed] [Google Scholar]
  23. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer : their use as an aid to early diagnosis. Ann Oncol 2007 ; 18 : 868-873. [CrossRef] [PubMed] [Google Scholar]
  24. Wang X, Yu J, Sreekumar A, Varambally S, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005 ; 353 : 1224-1235. [CrossRef] [PubMed] [Google Scholar]
  25. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 2007 ; 6 : 1115-1122. [CrossRef] [PubMed] [Google Scholar]
  26. Sahin U, Türeci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 199 ; 9: 709-716. [Google Scholar]
  27. Flahault A, Costagliola D. Is lung cancer screening by the helical scanner justified ? Med Sci (Paris) 2007 ; 23 : 333-334. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  28. Hill C. Critical interpretation of the cancer incidence increase in France. Med Sci (Paris) 2009 ; 25 : 297-299. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  29. Desmetz C, Mangé A, Solassol J. Comparison of proteomic strategies to identify antibodies resulting from the humoral immune response to cancer. Med Sci (Paris) 2008 ; 24 : 1071-1076. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  30. Julian-Reynier C. Prédisposition génétique aux cancers du sein et de l’ovaire : importance des résultats des tests. Med Sci (Paris) 2011 ; 27 : 657-661. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.